Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2
$599.00
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2
$599.00
A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.
SKU: N/A
Author: Datamonitor Healthcare
Publisher: Biomedtracker
Published: 02 October 2018
Number of pages:14
Formats:PDF
Report code:TL #10134
Highlights
Description
Highlights
“The biggest unmet needs are treating patients with refractory depression, and severe suicidal ideation, because those patients need something that is going to act quickly. Some of them start to give up after a point because they are not responding.”
“There is never going to be the perfect drug for every patient, and I think that it [brexanolone] is going to get a huge market share when it comes out, very good trials, very good data, a lot of time and effort put in to the drug.”
Drug Coverage
Abilify
ALKS 5461
BuSpar
Cymbalta
Esketamine
Fetzima
ketamine
Lexapro
Pristiq
Prozac
Rapastinel
Rexulti
SAGE-217
Seroquel
Travivo
Trintellix
Viibryd
Vraylar
Zulresso
Overview
A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.